Background.
On a national level it is known that the daily misuse of antibiotics leads to delayed recovery, increased hospital length of stay, recurrent infection and even death. At the organization-level, antimicrobial stewardship programs have been developed to tackle these issues. As these programs develop, research is greatly needed to assess the associated clinical outcomes. This study was conducted to compare such clinical outcomes as length of stay (LOS), 30 day readmission and mortality pre and post implementation of a formal antimicrobial stewardship program.
Methods. Retrospective review of randomized adult patients at a large community teaching facility receiving meropenem, linezolid, daptomycin, tigecycline, micafungin, vancomycin, piperacillin/tazobactam, levofloxacin, between April 2010 to March 2011 (Pre Intervention: n = 228) and April 2012 to March 2013 (Post Intervention: n = 219). The assessment of clinical outcomes was achieved using logistic regression for 30 day readmission and status of deceased on discharge, and a generalized linear model with gamma distribution for ICU LOS and inpatient LOS.
Results. The Pre Intervention group had a 30 day readmission rate of 16.7% (38/228), a Status on Discharge of Deceased of 10.5% (24/228), an ICU LOS of 13.4% (14/228), and an Inpatient LOS of 11.6% (10.5/228). In contrast, the Post intervention group had a 30 day readmission rate of 7.3% (16/219; P = 0.001), a Status on Discharge of Deceased of 3.7% (8/219; P = 0.002), an ICU LOS of 9% (7.9/219; P = 0.01), and an Inpatient LOS of 8.8% (7.6/219; P = 0.018).
Conclusion. The multidisciplinary efforts of the program were associated with statistical significant decreases in 30 day readmission rates, mortality on discharge and ICU and inpatient LOS. These results assist in validating the true clinical outcome benefits of antimicrobial stewardship programs.
Disclosures. Background. Antimicrobial stewardship programs (ASP) for oral antibiotics is limited, despite the fact that oral antibiotics account for 90% of total antibiotic consumption in developed countries. We aimed to analyze the effectiveness of ASP for oral antibiotics in a pediatric population.
Methods. We conducted a prospective study at a tertiary maternal and children fs hospital in Japan, consisting of 490 beds, with approximately 13,000 hospitalizations and 240,000 outpatient visits annually. Outpatient data on oral antimicrobial prescription, costs and proportions of resistant bacteria between 2013 and 2016 were analyzed. We conducted preauthorization and feedback as a means of intervention from October 2015 for targeted antimicrobials; vancomycin, linezolid, quinolones, faropenem, tebipenem pivoxil, polymyxin B. Antibiotic use density (AUD) was measured using days of therapy (DOT) /1000 visits. Interrupted time-series (ITS) analysis was performed to evaluate the effects of intervention.
Results. The main indications for use of targeted antimicrobials were urinary tract infections, pneumonia, and prophylactic administration in malignancy and were inappropriate in the majority prior to intervention. AUD and cost of targeted oral antimicrobials decreased from 11.0 DOT /1000 visits and 7,176 US dollars(USD) to 2.1 DOT/1000 visits and 1,665 USD, respectively (P < .001). ITS analysis showed that prescriptions for targeted antimicrobials decreased rapidly after initiation of preauthorization(-7.1 DOT /1000 visits; P < .001) (Figure 2-a) . Prescriptions for non-targeted oral antimicrobial increased temporarily (+28 DOT/1000 visits; P < .001), but a decreasing trend was found after the initiation (P < .001) (Figure 2-b) . During this study period, the susceptibility against quinolones did not change for E.coli, K.pneumoniae, and P.aeruginosa.
Conclusion. Introduction of the preauthorization system for selected oral antimicrobials decreased the AUD of both targeted and non-targeted antimicrobials.
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